Article
No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study.
European review for medical and pharmacological sciences - 1 Jun 2023
Li X-M, Wu Z-J, Xu Z-L, Li A, Liu M-Q, Song C-G, Wu K
Abstract excerpt
OBJECTIVE: Although many observational studies have shown an association between rosiglitazone and cardiovascular disease (CVD) or risk factors, controversy remains. We conducted a Mendelian randomized (MR) study to explore whether rosiglitazone is causally related to CVDs and risk factors. PATIENTS AND METHODS: Single-nucleotide polymorphisms associated with rosiglitazone at genome-wide significance were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.